Showing results (201-210 of 261) with videos related to
Sort By:
Pageof 27
Blood Advances|April 3, 2019
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host diseaseRoger Belizaire, Haesook T Kim, Samuel J Poryanda, et al.Blood Advances|May 7, 2020
BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantationEduardo Espada, Matthew P Cheng, Haesook T Kim, et al.Bone Marrow Transplantation|October 17, 2019
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiationZachariah DeFilipp, Shuli Li, David Avigan, et al.Blood|September 6, 2024
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphomaKatie Maurer, Isabella N Grabski, Roch Houot, et al.Blood Advances|August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 studyStephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.Nature Communications|December 31, 2024
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphomaJulia Paczkowska, Ming Tang, Kyle T Wright, et al.Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.Blood Advances|December 10, 2019
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasionKirsty Wienand, Bjoern Chapuy, Chip Stewart, et al.The Lancet. Haematology|June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S Davids, Danielle M Brander, Haesook T Kim, et al.Pageof 27